Drug Trial Radar · NCT04400331
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
154
Actual
Start
Sep 18, 2020
Primary completion
Nov 5, 2025
Study completion Nov 5, 2025
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- Collaborators
- Huntington Study Group
- First posted
- May 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
Conditions
- Chorea, Huntington
Interventions
ValbenazineDrug
vesicular monoamine transporter 2 (VMAT2) inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 262 weeks
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Birmingham, Alabama
Neurocrine Clinical Site
Little Rock, Arkansas
Neurocrine Clinical Site
La Jolla, California
Neurocrine Clinical Site
Aurora, Colorado
Neurocrine Clinical Site
Washington D.C., District of Columbia
Neurocrine Clinical Site
Boca Raton, Florida
Neurocrine Clinical Site
Gainesville, Florida
Neurocrine Clinical Site
Atlanta, Georgia
Neurocrine Clinical Site
Chicago, Illinois
Neurocrine Clinical Site
Chicago, Illinois
Neurocrine Clinical Site
Indianapolis, Indiana
Neurocrine Clinical Site
Iowa City, Iowa
Neurocrine Clinical Site
Wichita, Kansas
Neurocrine Clinical Site
Louisville, Kentucky
Neurocrine Clinical Site
New Orleans, Louisiana
Neurocrine Clinical Site
Boston, Massachusetts
Neurocrine Clinical Site
Charlestown, Massachusetts
Neurocrine Clinical Site
Ann Arbor, Michigan
Neurocrine Clinical Site
Omaha, Nebraska
Neurocrine Clinical Site
Rochester, New York
Neurocrine Clinical Site
Williamsville, New York
Neurocrine Clinical Site
Durham, North Carolina
Neurocrine Clinical Site
Columbus, Ohio
Neurocrine Clinical Site
Toledo, Ohio
Neurocrine Clinical Site
Pittsburgh, Pennsylvania
Neurocrine Clinical Site
Charleston, South Carolina
Neurocrine Clinical Site
Columbia, South Carolina
Neurocrine Clinical Site
Greenville, South Carolina
Neurocrine Clinical Site
Nashville, Tennessee
Neurocrine Clinical Site
Houston, Texas
Neurocrine Clinical Site
Burlington, Vermont
Neurocrine Clinical Site
Vancouver, British Columbia, Canada
Neurocrine Clinical Site
Ottawa, Ontario, Canada
Neurocrine Clinical Site
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.